Osteopenia and Perimenopause: A Complete Guide to Low Bone Density
Diagnosed with osteopenia during perimenopause? This guide explains what it means, your fracture risk, and the best ways to protect your bones.
What Osteopenia Actually Means
Osteopenia is not a disease. It is a description of bone density that sits below the average for a young healthy adult but has not yet reached the threshold for osteoporosis. On a DEXA scan, a T-score between -1.0 and -2.5 places you in the osteopenia range. The word itself comes from Greek meaning deficiency of bone. Many women receive this result during perimenopause and feel alarmed, but context matters enormously. A T-score of -1.1 is very different from -2.4 in terms of actual fracture risk. Osteopenia is common. Studies suggest that around half of postmenopausal women in Western countries have osteopenia, and a significant proportion of perimenopausal women are already in this range. It is a finding that calls for action, not panic.
Why Perimenopause Accelerates Bone Loss
Estrogen plays a central role in regulating bone remodelling, the continuous cycle in which old bone is broken down by cells called osteoclasts and new bone is laid down by osteoblasts. When estrogen levels decline during perimenopause, osteoclast activity accelerates while osteoblast activity lags behind. The result is a net loss of bone tissue. This process begins even before the final period and continues through the early postmenopausal years at a rate that can reach two to three percent annually at the hip and spine. Women who enter perimenopause with lower peak bone mass, which is partly genetic but also influenced by nutrition, exercise, and lifestyle in earlier decades, have less reserve and reach the osteoporosis threshold sooner. That is why early detection through a DEXA scan is worthwhile for women with risk factors.
Assessing Your True Fracture Risk
Bone density alone does not determine fracture risk. A tool called FRAX (Fracture Risk Assessment Tool), developed by the World Health Organisation, calculates your 10-year probability of a major osteoporotic fracture and a hip fracture specifically. It incorporates your T-score alongside other factors: age, sex, BMI, previous fracture history, parental hip fracture, smoking, alcohol use, glucocorticoid use, rheumatoid arthritis, and secondary causes of osteoporosis. Many women with osteopenia have a low FRAX score, meaning their absolute fracture risk over 10 years is modest and lifestyle intervention alone is appropriate. Others, particularly older perimenopausal women with multiple risk factors, may have a high enough score to warrant medication even before their T-score drops to -2.5. Ask your doctor to run a FRAX calculation with your results.
Lifestyle Interventions That Genuinely Work
For most women with osteopenia, lifestyle changes are the cornerstone of management. Weight-bearing and impact exercise provides the mechanical loading that stimulates bone formation. Jogging, brisk walking, hiking, aerobics, and jumping all count. Resistance training adds further benefit by building the muscle that protects bone and reduces fall risk. Two to three strength training sessions per week are recommended. Calcium intake should reach 1,000 to 1,200 mg per day for perimenopausal women. Dairy products, calcium-set tofu, sardines and salmon with bones, almonds, and kale are good dietary sources. Supplements can fill gaps but food first is the principle. Vitamin D is essential for calcium absorption and bone mineralisation. A blood level above 50 nmol/L is generally considered adequate. Many perimenopausal women are deficient and need 800 to 2,000 IU daily. Quit smoking. Limit alcohol to under 14 units weekly. Both have direct negative effects on bone cell activity.
When Medication Is Considered
Not all women with osteopenia need drug treatment. The decision depends on FRAX score, rate of bone loss, and individual circumstances. If a repeat DEXA after two years shows continued significant decline despite lifestyle measures, or if FRAX risk is high, treatment may be recommended. The most commonly prescribed options are bisphosphonates such as alendronate or risedronate, which reduce osteoclast activity and slow bone resorption. They are taken weekly or monthly and are generally well tolerated, though they require specific swallowing instructions to avoid oesophageal irritation. HRT is a strong option for perimenopausal women because it addresses both the hormonal root cause of accelerated bone loss and other menopause symptoms simultaneously. Evidence supports HRT's effectiveness in preventing bone loss and fractures, and it is increasingly recommended for women under 60 who have no contraindications. Denosumab and raloxifene are alternatives for specific situations.
Monitoring and Long-Term Outlook
Osteopenia does not automatically progress to osteoporosis, and many women stabilise or even improve their bone density with intervention. If you are making lifestyle changes and no medication has been started, a repeat DEXA in three to five years is a reasonable interval. If you are on treatment, a two-year repeat scan helps assess response. Bring all your results to each appointment for comparison. Some women with osteopenia fracture a wrist or vertebra before diagnosis, which is a wake-up call that the standard screening criteria may have been too conservative for them individually. If you have had any fracture from a low-impact event such as a fall from standing height, discuss it urgently with your doctor as it changes your fracture risk category regardless of your T-score. The prognosis with appropriate management is good. Bones respond to the right stimulus at any age.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.